FcyRllb, CD22, and CD72 are important negative regulatory molecules which fine tune the immuneresponses through an intracellular signaling pathway which includes the Src-family tyrosine kinase Lyn.Knockout and transgenic animals regarding these regulatory molecules ALL develop features of lupusljkeautoimmunity. Both lyn knockout mice and lyn gain-of-function transgenic mice also develop a lupus-likeautoimmune phenotype characterized by hyper-responsive B cells and increase autoantibody production.Differences in Lyn protein expression, sub-cellular localization and post-translational modifications in B cellsand hematopqetic cells have been described in lupus patients compared to controls. However, no humangenetic association studies of LYN exists to date. LYN therefore remains a strong lupus candidate genebased on function and candidate pathway analysis.We have now identified a strong genetic association with LYN and human lupus. We targeted LYN in acandidate gene genetic association study of 697 cases and 604 controls testing 22 SNPs. We identifiedmultiple SNPs with strong associations. The peak association gave a x2=10.42, p=0.0012, OR=1.43 95%Cl (1.16-1.78) and we identified a 3-marker haplotype CTA that confers lupus risk x2=8.35, p=0.0039,OR=1.34 (95% Cl:1.10-1.63) and one GAG that confers protection from lupus x2=11.23, p=0.0008,OR=0.69 (95% Cl: 0.56-0.86).The focus of this feasibility study is to characterize the genetic association results we have discoveredwhich link human LYN to SLE development.
Our specific aims are to 1.) identify polymorphism in LYN thatphysically map the genetic association with lupus, 2.) fine map the LYN genetic association in a larger lupuscohort with additional SNPs, and 3.) explore the potential genetic mechanisms of LYN association and risk ofSLE development for functional differences in Lyn protein associated with risk.Understanding the genetic polymorphism(s) that alter Lyn function and increases risk of developing SLEor alternatively protecting one from developing lupus is crucial to understanding how to intervene in thisdevastating disease process. These studies will help determine what cells and what pathogenic mechanismsLyn polymorphism impact that lead to increased risk of developing lupus. Each of these questions need to bemore fully addressed so that researchers can target those pathways most clinically important to lupus.Summary: This study seeks to identify and characterize a gene that contributes to SLE risk. Identifyingsuch genes will be important to understanding how this devastating and complex disease develops and alsowhat new molecular targets can be considered for therapeutic development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053483-02
Application #
7680457
Study Section
Special Emphasis Panel (ZAR1-KM-K (M1))
Project Start
2008-09-01
Project End
2012-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
2
Fiscal Year
2008
Total Cost
$77,457
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531
Jog, Neelakshi R; Chakravarty, Eliza F; Guthridge, Joel M et al. (2018) Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Front Immunol 9:2198
Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824
Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :
Scofield, R Hal; Sharma, Rohan; Harris, Valerie M (2018) Reply. Arthritis Rheumatol 70:626-627
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480
Martínez-Bueno, Manuel; Oparina, Nina; Dozmorov, Mikhail G et al. (2018) Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci 19:
Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113

Showing the most recent 10 out of 284 publications